Product Description: Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21(19):4286-93./[2]Zhenglin Ou, et al. Pressure increases PD‑L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti‑ROR1 CAR T cell‑mediated cytotoxicity, Sci Rep/[3]Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21(19):4286-93./[4]Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.
CAS Number: 1374853-91-4
Molecular Weight: N/A
Compound Purity: 99.06
Research Area: Cancer
Solubility: H2O
Target: PD-1/PD-L1
English
Deutsch
